Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – Asia,
Asia: South Korea
Korean cancer screening company seeks investment.
The Korean company's core technology is nanoscale controllable surface coating technology. The company aims to reliably diagnose early human cancer through the highest sensitivity, specificity and lowest detection limit. Through 15 years of research and investment of USD 20 million, the company has completed the R&D of core technology. In vitro diagnosis ("IVD") has been applied and four cardiac lateral flow immunoassay ("LFA") (sidestream analysis) kits have been completed pilotscale experiment. The company has registered patents in 12 countries including the United States and the European Union. The company now seeks investment.
Asia: Israel
Israeli wound healing technology company seeks investment for market expansion.
The Israeli company develops exclusive wound healing technology products, which promote wound healing by using synthetic negatively charged microspheres ("NCM") to stimulate cells involved in wound healing and tissue regeneration. The company's most advanced wound healing products are classified as IIb medical devices in Europe and are manufactured by factories with European Conformity ("CE") mark certification. The company's products are currently sold in the European Union and some Latin American countries, and it plans to enter the American and Canadian markets. Now the company seeks investment.
Asia: Japan
Japanese hospital seeks Chinese partners and to sell 60% or more equity.
The Japanese hospital has the following diagnosis and treatment departments: neurosurgery, nephrology, hematology, respiratory, gastroenterology, cardiovascular, endocrinology, pediatrics, surgery, orthopaedics, psychiatry, neurology, dental and oral surgery, rehabilitation, anesthesiology, otorhinolaryngology, urology, ophthalmology and gynecology. The hospital has 296 beds and can undertake medical travel projects. It seeks Chinese partners and to sell 60% or more equity.
Asia: Hong Kong SAR
Hong Kong owned Foshan medical clinic seeks new owner or cooperation.
The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics, pediatrics, pediatric surgery, children's health care, ophthalmology, otorhinolaryngology, stomatology, dermatology, traditional Chinese medicine inspection, imaging (ultrasound, electrocardiogram ("ECG")). The expiry date of the clinic lease is July 31, 2028. The medical licence is valid until 2026. The company has professional qualifications in ophthalmology, stomatology and dermatology and decoration equipment. It has 24 consulting rooms and 2 dental chairs. It is brand new high-end decorated, which has not yet been opened for use, and is ready for opening at any time. The company is Hong Kong-listed. It seeks the sale of the outpatient department clinic in Foshan or cooperation.
Asia: Hong Kong SAR
Hong Kong owned Foshan medical clinic seeks new owner or cooperation.
The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics, pediatrics, child health care, ophthalmology, otorhinolaryngology, stomatology, traditional Chinese medicine inspection, and imaging (ultrasound, electrocardiogram ("ECG")). The expiry date of the clinic lease is July 31, 2029. The medical licence is valid till 2025. The company is surrounded by high-end residential and commercial areas. It has ophthalmology and stomatology qualifications and decoration settings. Besides, it has 9 consulting rooms, complete treatment room, laboratory and ultrasound room. It is Hong Kong-listed. The company seeks the sale of the clinic in Foshan or cooperation.
Asia: Hong Kong SAR
Hong Kong owned Suzhou pediatric clinic seeks new owner or cooperation.
The Hong Kong company engages in pediatrics and laboratory. It has 2 complete consulting rooms and 1 laboratory. The expiry date of the clinic lease is July 15, 2023. The company is Hong Kong-listed. It seeks the sale of the clinic in Suzhou or cooperation.
Asia: Hong Kong SAR
Hong Kong owned Chengdu children health center seeks new owner or cooperation.
The Hong Kong company engages in children's health care, which does not require the application for medical practice licence. The expiry date of the clinic lease is December 31, 2030. The company is Hong Kong-listed. It seeks the sale of the clinic in Chengdu or cooperation.
Asia: Hong Kong SAR
Hong Kong owned Chengdu clinic seeks new owner or cooperation.
The Hong Kong company's scope of medical qualifications include internal medicine, pediatrics, gynecology, surgery, women's health care, children's health care, ophthalmology, otorhinolaryngology, stomatology, dermatology, traditional Chinese medicine inspection, and imaging (ultrasound). The company has a comprehensive medical licence and the speciality qualification and decoration setting of dermatology, stomatology and women's and children's health care. It is Hong Kong-listed. Its medical licence is valid from May 26, 2020 to May 25, 2025. The company seeks the sale of the clinic in Chengdu or cooperation.
Asia: Hong Kong SAR
Hong Kong owned Beijing clinic seeks new owner or cooperation.
The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics (gynecology), pediatrics, ophthalmology, otorhinolaryngology, stomatology, dermatology, psychiatry, traditional Chinese medicine inspection, and imaging (X-ray, ultrasound, electrocardiogram ("ECG")). In the Chaoyang district of Beijing, the comprehensive outpatient department licence is scarce. The company is Hong Kong-listed. It seeks the sale of the clinic in Beijing or cooperation.
Asia: Israel
Israeli sales analytics company seeks USD 3 million financing.
Through professional data analysis, the Israeli company's Software as a Service ("SaaS") platform helps distribution companies improve sales and profits. The company's product has insightful proprietary algorithms that analyze the company's sales and marketing data and external data sets to provide sales and marketing agents with specific recommended action "insights" on how to increase revenue and where to realize unrealized business opportunities. Existing data show that one month's use has brought 14% additional revenue to customers. The company seeks USD 3 million financing.
Asia: South Korea
Korean Alzheimer's diagnosis technology company seeks investment.
The Korean company's Alzheimer's diagnosis technology has the original myelodysplastic syndromes ("MDS") technology (polymer detection technology), which is an original technology for early diagnosis of protein conformational diseases. The company has developed products for early and accurate diagnosis of Alzheimer's disease through blood samples. The company's original MDS technology can be used as a platform technology for diagnosis of all protein conformational diseases. Compared with current technology, the company's Blood Amyloid-β Oligomerization detection technology has the advantages of small amount of blood collection, simple method, quantitative detection, no need for expensive analytical instruments, early diagnosis and so on. In the future, based on MDS platform technology, the company's technology can also be used to detect Parkinson's disease. The company now seeks investment.
Asia: South Korea
Korean biopharma company seeks investment.
The Korean company began to expand its products since 2011, when it obtained the product licence of hyaluronic acid ("HA") injections. It has obtained the patent for manufacturing equipment and method of HA inducible factor. The company's anti-adhesion materials have obtained Good Manufacturing Practice ("GMP") certification and the collagen repair patch has obatined the medical device certification. The company has completed the botulinum toxin clinical phase I and II (phase III investigational new drug ("IND") application) trials, which were listed in the Korean Securities Dealers Automated Quotations ("KOSDAQ"). At present, the company's medical device factory in Daegu is a special factory for biomedical instruments, which can produce mesotherapy products such as HA/DNA injections, wound repair and tissue supplement materials, etc. in a modular manner. In the future, an Sejong GMP factory will be added for mass production of specialized medicines, bulk medicines, botulinum toxin, peptide for treating brain diseases, antiviral medicines for liver diseases, etc. In 2019, the company's export reached USD 6.24 million (KRW 7.8 billion) with 40 export countries. The company now seeks investment.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us